Lifted the veil of peritoneal mucinous tumors!

 Lifted the veil of peritoneal mucinous tumors!
Under the veil is a strange world, shrouded in a veil for something, people become aware of their true nature will certainly be very different. This is the human understanding of things is an objective process . peritoneal mucinous tumors because of its low incidence, when the doctor when it is truly meet to understand the textbook even though the description of its prognosis, but often it will be the appearance of the zheng zhu terrible, so the vast majority of doctors will have the disease after surgery or the prognosis will be made wrong judgments, not as a result of surgery, postoperative patients are deprived of the right treatment. The patient and the patient's family to give up because of medical treatment or to determine input in a variety of informal ways to treat, and finally spent the money, subject to guilt without any effect. Today, just a myxoma patient counseling, I think their very universality of the medical process, and uncover the veil of peritoneal mucinous tumors are to help, so close this article. hope that patients and doctors access to the peritoneal disease have a better understanding myxoma. for the patient to do more useful work.
peritoneal mucinous tumors in the end is what disease? < br> peritoneal mucinous tumors, also known as pseudomyxoma peritonei is a rare to have mucous cells in the peritoneal and produce a large jelly-like disease characterized by mucus, mostly secondary to appendiceal mucocele, mucinous ovarian cystadenoma, cystadenocarcinoma or mucinous adenocarcinoma of the gastrointestinal tract, for a low-grade malignant lesions (tumors that are not objective, it should still belong to cancer.) is characterized by the proliferation of lymphatic or blood vessels, only grown in the peritoneal or mesenteric infiltration of surface and not to the organ, while a large amount of mucinous ascites. in other words to explain: mucinous carcinoma of the appendix and pseudomyxoma peritonei has grown to the abdominal cavity and the characteristics of mucus secretion, but their cultivation lesions without lymph node metastasis and blood, not to organ infiltration, only to seize the abdominal cavity and abdominal organs with limited space, and finally squeezed the normal abdominal organs Erzhi abdominal distension, intestinal obstruction, feeding difficulties and so on. Therefore, we call it as low grade. appendiceal mucinous carcinoma (also known as cystadenocarcinoma appendix) are in the appendix of a mucus cyst. appendiceal mucocele is rare in clinical practice is not, of which 75-85% belong to the benign, The extremely rare cystadenocarcinoma appendix, appendiceal mucinous cysts reported in the literature 10%. The clinical diagnosis is difficult, even in the fast-frozen section examination because the tumor was strong mucus secretion, a relatively small component of tumor cells, also pathology at this time difficult to determine the benign or malignant. because of clinically asymptomatic, virtually 100% of preoperative misdiagnosis. pathologically confirmed cancer before making a second operation. Most scholars of appendiceal mucinous adenocarcinoma and pseudomyxoma peritonei in favor of complete tumor to tumor or reduce post-operative adjuvant intraperitoneal chemotherapy. intraperitoneal hyperthermic chemotherapy in the adjuvant treatment respected. The prognosis of this disease is still good, although about 50% to 70% of patients finally relapse, the overall 5 year survival rate is about 50% to 70% of the .10-year survival rate was 65%, even in patients with peritoneal pseudo myxoma 5-year survival rate can reach 50%. As the disease rare, and difficult to distinguish between the early pathology of the benign and malignant, the surgeon lack of knowledge about the disease, in tumors and tumor reduction surgery, to not enough confidence and patience, and the high recurrence rate of this disease, leading to repeated surgery of this disease, but the overall effect is not satisfactory. I Feature article, the purpose is to warn surgical colleagues, the appendix mucinous carcinoma or pseudomyxoma peritonei to be positive in the surgical treatment, no such technology if the local level, should go on a hospital, patients and their families take active mobilization surgery, should not give up easily mobilized surgery patients and their families.
What is perfusion chemotherapy?
perfusion chemotherapy combined application of chemotherapy and hyperthermia treatment of cancer, a new therapy. perfusion chemotherapy treatment principle: its is the use of thermal heating effect of good physical energy chemotherapy, perfusion to the tumor site, tumor tissue temperature to rise to the effective treatment temperature (42.5 ℃ m43.5 ℃) for 60 to 120 minutes, both the destruction of tumor cells to normal tissue without damage (normal tissue cells of the temperature safety limit of 45 ℃ + / -1 ℃) in a way. perfusion chemotherapy on tumor cells not only have a direct cytotoxic effect, but also can enhance chemotherapy, radiation therapy, improve the body's immune system , inhibit tumor metastasis. perfusion chemotherapy in China, began in the nineties. What to do perfusion chemotherapy for cancer? for lung, stomach, esophagus, liver cancer, colorectal cancer (appendix mucinous carcinoma), peritoneal pseudo-mucinous tumor (cancer), ovarian cancer (ovarian mucinous tumor, or cancer), various types of sarcoma, breast cancer, ascites and pleural fluids and late intractable pain and other symptoms of the patient's treatment. perfusion chemotherapy effects? stomach intestinal tumor often occurs abdominal organs, peritoneum, abdominal lymph node metastases, even after surgery patients, the incidence of peritoneal metastasis is very high, is one of the main causes of death in patients. generally in the median survival period of several weeks or months, one year survival rate of less than 10% .1980 was first proposed in spratl continuous peritoneal perfusion chemotherapy, and later the Japanese to break through the full thickness of the gastric cancer underwent CHPP, and conducted a systematic randomized studies that obtained convincing of the positive conclusion: CHPP tissue when the concentration of drug in the abdominal cavity is much higher than plasma concentrations, even up to 1000 times, Moreover, the absorption of the peritoneal cavity, portal system, the drug concentration up to 10 times more than the peripheral blood, which is the treatment of liver cancer, pancreatic cancer has a good help. Glehen University of Lyon, France published a prospective study so that heat peritoneal metastasis of gastric cancer patients with chemotherapy have better therapeutic effect, especially in preoperative ascites, and had received no effective cytoreductive surgery in patients. Glehen pointed out that the majority of gastric cancer patients because of peritoneal metastasis, but only received palliative surgery and easy recurrence, more aggressive treatment of the current methods are mainly the peritoneal cavity immediately after chemotherapy, to expand peritoneal resection combined with intraperitoneal chemotherapy. Glehen that cytoreductive surgery combined with intraperitoneal chemotherapy for peritoneal metastasis of gastric cancer patients to improve survival and effective.
peritoneal myxoma
effective treatment through surgery to maximize the after cytoreductive peritoneal perfusion chemotherapy. Although about 50% to 70% of patients finally relapse, the overall 5-year survival rate is about 50% to 70% of the .10-year survival rate was 65%, even if false mucinous peritoneal 5-year survival in patients with tumors can reach 50%. the prognosis is still good. It intravenous chemotherapy and radiotherapy are not very sensitive to the intraperitoneal chemotherapy in pseudomyxoma peritonei (cancer) of adjuvant therapy in highly respected.